General Catalyst led a $168m Series B round in Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, with participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, SVB Securities, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. "Odyssey is pioneering next generation therapeutics by marrying a powerful drug discovery engine integrating machine learning, biology, and medicinal and structural chemistry with an exceptional leadership team of proven drug developers. We are pleased to partner with General Catalyst and our world-class syndicate of investors and believe the interest in our immunology and oncology pipeline and capabilities further validates our approach to therapeutic development. We have made tremendous strides since our launch in 2021, and we value the support as we advance multiple candidates into IND-enabling studies in 2023," Gary D. Glick, Odyssey Therapeutics Founder and CEO.